BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 28522740)

  • 21. Pilot Comparison of ⁶⁸Ga-RM2 PET and ⁶⁸Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer.
    Minamimoto R; Hancock S; Schneider B; Chin FT; Jamali M; Loening A; Vasanawala S; Gambhir SS; Iagaru A
    J Nucl Med; 2016 Apr; 57(4):557-62. PubMed ID: 26659347
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early dynamic imaging in
    Uprimny C; Kroiss AS; Decristoforo C; Fritz J; Warwitz B; Scarpa L; Roig LG; Kendler D; von Guggenberg E; Bektic J; Horninger W; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2017 May; 44(5):765-775. PubMed ID: 27900519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determination of whole-body tumour burden on [68Ga]PSMA-11 PET/CT for response assessment of [177Lu]PSMA-617 radioligand therapy: a retrospective analysis of serum PSA level and imaging derived parameters before and after two cycles of therapy.
    Michalski K; Mix M; Meyer PT; Ruf J
    Nuklearmedizin; 2019 Dec; 58(6):443-450. PubMed ID: 31724145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. (68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer.
    Sachpekidis C; Eder M; Kopka K; Mier W; Hadaschik BA; Haberkorn U; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1288-99. PubMed ID: 26753602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes.
    Barbaud M; Frindel M; Ferrer L; Le Thiec M; Rusu D; Rauscher A; Maucherat B; Baumgartner P; Fleury V; Colombié M; Thierry-Morel A; Kraeber-Bodéré F; Campion L; Rousseau C
    Prostate; 2019 Apr; 79(5):454-461. PubMed ID: 30549066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of
    Hope TA; Aggarwal R; Chee B; Tao D; Greene KL; Cooperberg MR; Feng F; Chang A; Ryan CJ; Small EJ; Carroll PR
    J Nucl Med; 2017 Dec; 58(12):1956-1961. PubMed ID: 28522741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of standard and delayed imaging to improve the detection rate of [
    Schmuck S; Nordlohne S; von Klot CA; Henkenberens C; Sohns JM; Christiansen H; Wester HJ; Ross TL; Bengel FM; Derlin T
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):960-968. PubMed ID: 28280856
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined Early and Late [
    Hohberg M; Kobe C; Täger P; Hammes J; Schmidt M; Dietlein F; Wild M; Heidenreich A; Drzezga A; Dietlein M
    Mol Imaging Biol; 2019 Jun; 21(3):558-566. PubMed ID: 30105521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence.
    Uprimny C; Kroiss AS; Fritz J; Decristoforo C; Kendler D; von Guggenberg E; Nilica B; Maffey-Steffan J; di Santo G; Bektic J; Horninger W; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1647-1655. PubMed ID: 28589253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PSA levels, PSA doubling time, Gleason score and prior therapy cannot predict measured uptake of [68Ga]PSMA-HBED-CC lesion uptake in recurrent/metastatic prostate cancer.
    Verburg FA; Pfister D; Drude NI; Mottaghy FM; Behrendt FF
    Nuklearmedizin; 2017; 56(6):225-232. PubMed ID: 29044297
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Farolfi A; Ceci F; Castellucci P; Graziani T; Siepe G; Lambertini A; Schiavina R; Lodi F; Morganti AG; Fanti S
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):11-19. PubMed ID: 29905907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective comparison of whole-body MRI and
    Sawicki LM; Kirchner J; Buddensieck C; Antke C; Ullrich T; Schimmöller L; Boos J; Schleich C; Schaarschmidt BM; Buchbender C; Heusch P; Rabenalt R; Albers P; Antoch G; Müller HW; Hautzel H
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1542-1550. PubMed ID: 30879122
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Vinsensia M; Chyoke PL; Hadaschik B; Holland-Letz T; Moltz J; Kopka K; Rauscher I; Mier W; Schwaiger M; Haberkorn U; Mauer T; Kratochwil C; Eiber M; Giesel FL
    J Nucl Med; 2017 Dec; 58(12):1949-1955. PubMed ID: 28637799
    [No Abstract]   [Full Text] [Related]  

  • 34. The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels.
    Kabasakal L; Demirci E; Nematyazar J; Akyel R; Razavi B; Ocak M; Aygun A; Obek C; Kural AR
    Nucl Med Commun; 2017 Feb; 38(2):149-155. PubMed ID: 27893589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 68Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer.
    Fendler WP; Schmidt DF; Wenter V; Thierfelder KM; Zach C; Stief C; Bartenstein P; Kirchner T; Gildehaus FJ; Gratzke C; Faber C
    J Nucl Med; 2016 Nov; 57(11):1720-1725. PubMed ID: 27261520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with
    Ferraro DA; Rüschoff JH; Muehlematter UJ; Kranzbühler B; Müller J; Messerli M; Husmann L; Hermanns T; Eberli D; Rupp NJ; Burger IA
    Theranostics; 2020; 10(14):6082-6094. PubMed ID: 32483440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of
    Walacides D; Meier A; Knöchelmann AC; Meinecke D; Derlin T; Bengel FM; Ross TL; Wester HJ; Derlin K; Kuczyk MA; von Klot CAJ; Christiansen H; Henkenberens C
    Strahlenther Onkol; 2019 May; 195(5):420-429. PubMed ID: 30610354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy, Predictive Factors, and Prediction Nomograms for
    Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
    Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathological predictors of positive
    Aydin AM; Haberal B; Artykov M; Bilen CY; Yazici S
    Ann Nucl Med; 2019 May; 33(5):326-332. PubMed ID: 30778860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in
    Freitag MT; Radtke JP; Afshar-Oromieh A; Roethke MC; Hadaschik BA; Gleave M; Bonekamp D; Kopka K; Eder M; Heusser T; Kachelriess M; Wieczorek K; Sachpekidis C; Flechsig P; Giesel F; Hohenfellner M; Haberkorn U; Schlemmer HP; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2017 May; 44(5):776-787. PubMed ID: 27988802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.